Drug Profile
Oxytocin intranasal - Vyera Pharmaceuticals
Alternative Names: Syntocinon Nasal Spray; TUR 001Latest Information Update: 04 Dec 2021
Price :
$50
*
At a glance
- Originator Novartis Pharmaceuticals Corporation
- Developer Retrophin; Turing Pharmaceuticals; University of California, San Diego
- Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autistic disorder; Lactation failure; Schizophrenia
Most Recent Events
- 17 Aug 2018 University of North Carolina at Chapel Hill plans the phase II OT-ETOH-4 trial for Alcoholism (In adults, In the elderly) in USA (Intranasal) (NCT03636555)
- 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
- 15 Feb 2017 Discontinued - Clinical-Phase-Unknown for Schizophrenia (Adjunctive treatment) in USA (Intranasal)